Press releasePRNewswire
Cardiol Therapeutics
CRDL · TORONTO
$1.12−$0.03 (−2.61%)TodayMarket closed ·
Prev close $1.15
Latest news
- Press releasePRNewswire
Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds
- News
Cardiol Therapeutics Files $150M Base Shelf Prospectus, Enabling Future Offerings Of Shares, Debt, Warrants And Other Securities
- Press releasePRNewswire
Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission
- Press releasePRNewswire
Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- Press releasePRNewswire
Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference
- Press releasePRNewswire
Cardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association
- Press releasePRNewswire
Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit
- Press releasePRNewswire
Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders
- Press releasePRNewswire
Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT
- Press releasePRNewswire
Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ
- Press releasePRNewswire
Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association
- Press releasePRNewswire
Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program
- Press releaseNewsfile
Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart
- News
Cardiol Advances Key Studies and Secures Funding to Push New Heart Treatments Forward
- Press releaseNewsfile
Cardiol Therapeutics Announces Year-End 2025 Update on Operations
- Press releaseNewsfile
Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference
- Press releaseNewsfile
Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure
- Press releaseNewsfile
Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million
- Press releaseNewsfile
Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million
- Press releaseNewsfile
Cardiol Therapeutics Inc. Announces Bought Deal Financing for Gross Proceeds of $13.5 Million
- Press releaseNewsfile
Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
- NewsAvi Kapoor
Why MongoDB Shares Are Trading Higher By Over 22%; Here Are 20 Stocks Moving Premarket
- Press releaseNewsfile
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions
- Press releaseNewsfile
Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040
- Press releaseNewsfile
Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases
- Press releaseNewsfile
Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027
- News
Cardiol Therapeutics Completes $11M Private Placement Selling 11M Units At $1/Unit; Says MAVERIC Phase III Pivotal Trial Of Orphan Drug Candidate CardiolRx In Recurrent Pericarditis Is Fully Funded Through To A Planned NDA Submission With The FDA; Data From The ARCHER Trial To Be Presented At A Cardiology Conference In November 2025
- Press releaseNewsfile
Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027
- Press releaseNewsfile
Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders
- Press releaseNewsfile
Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors
- NewsNina Zdinjak
CBD-Based Drug Reduces Pericarditis Pain And Inflammation, Shows New Clinical Study
- NewsHenry Khederian
Why Cardiol Therapeutics (CRDL) Stock Is Down 20% Today
- NewsAvi Kapoor
AZZ, Helen of Troy And 3 Stocks To Watch Heading Into Wednesday
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.